HonCode

Go Back   HER2 Support Group Forums > her2group
Reload this Page Her2 conference...It never hurts to see what the researchers are talking about
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 05-07-2007, 09:35 AM   #1
Vicki
Senior Member
 
Join Date: Jun 2006
Posts: 44
Her2 conference...It never hurts to see what the researchers are talking about
<TABLE cellSpacing=0 cellPadding=0 width=600 align=center border=0><TBODY><TR><TD>If you are unable to view the graphics, click here to view e-mail online

</TD></TR></TBODY></TABLE><TABLE cellSpacing=0 cellPadding=0 width=600 align=center background=http://cancerconferences.com/HTML_email/Breast/paradigmsbc_0607/bg.gif border=0><TBODY><TR><TD></TD></TR><TR><TD vAlign=top><TABLE cellSpacing=0 cellPadding=2 width=580 align=center border=0><TBODY><TR><TD vAlign=top>
Chairs:
Mark Pegram, MD
Los Angeles, CA

Michael Untch, MD, PhD
Berlin, Germany


<TABLE cellSpacing=0 cellPadding=0 width=575 align=center border=0><TBODY><TR><TD class=body1 vAlign=top width=70> </TD><TD class=body1 vAlign=top width=293>Agenda</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Faculty

View Complete Faculty Details</TD></TR><TR><TD class=body1 vAlign=top> </TD><TD class=body1 vAlign=top> </TD><TD class=body1 vAlign=top> </TD><TD class=body1 vAlign=top> </TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70 bgColor=#f5f0d9>1:00 pm</TD><TD class=body1 vAlign=top width=293 bgColor=#f5f0d9>Registration and Reception

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>

</TD></TR><TR><TD class=body1 vAlign=top width=70>1:30 pm</TD><TD class=body1 vAlign=top width=293>Welcome and Overview

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>

</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>1:35 pm</TD><TD class=body1 vAlign=top width=293>Targeting HER2 in Early Breast Cancer: Progress in Individualizing Therapy

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Edward Romond, MD
Lexington, KY

</TD></TR><TR><TD class=body1 vAlign=top width=70>1:55 pm</TD><TD class=body1 vAlign=top width=293>Novel Approaches to HER2-Positive Breast Cancer: Emerging Targeted Agents

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Mark Pegram, MD
Los Angeles, CA

</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>2:15 pm</TD><TD class=body1 vAlign=top width=293>Practical Considerations for Angiogenesis Inhibition in Advanced Breast Cancer

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Ruth O’Regan, MD
Atlanta, GA

</TD></TR><TR><TD class=body1 vAlign=top width=70>2:35 pm</TD><TD class=body1 vAlign=top width=293>Multiplying the Benefits: Novel Combinations of Targeted Agents

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Michael Untch, MD, PhD
Berlin, Germany

</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>2:55 pm</TD><TD class=body1 vAlign=top width=293>Cooperative Mutations: Potential Contributions of c-MYC Amplification and Other Genetic Alterations in HER2-Positive Breast Cancer

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>Soonmyoung Paik, MD
Pittsburgh, PA

</TD></TR><TR><TD class=body1 vAlign=top width=70>3:15 pm</TD><TD class=body1 vAlign=top width=293>Question-and-Answer Session

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>

</TD></TR><TR bgColor=#f5f0d9><TD class=body1 vAlign=top width=70>3:30 pm</TD><TD class=body1 vAlign=top width=293>Adjourn

</TD><TD class=body1 vAlign=top width=12> </TD><TD class=body1 vAlign=top width=200>

</TD></TR></TBODY></TABLE>
<HR SIZE=1>Program Overview

The New Paradigms in the Biologic Therapy of Breast Cancer: Translating Advances in Molecular Biology Into Improved Patient Outcomes satellite symposium will educate physicians on the latest advances in biologic therapies for breast cancer, with a focus on HER2<SUP>+</SUP> disease. One lecture will be devoted to the potential for optimizing and individualizing HER2-targeted therapy for early-stage breast cancer, while a second will explore new agents targeting this pathway in metastatic disease. A third lecture will focus on the use of angiogenesis inhibitors. Two additional lectures will review activation pathways or genomic mutations, respectively, that cooperate with HER2 signaling in neoplasia and therapy combination strategies aimed at preventing the emergence of resistance via activation of alternate growth or survival signals.

This presentation was selected by the American Society of Clinical Oncology<SUP>®</SUP> as an independent educational activity held in conjunction with an ASCO<SUP>®</SUP> meeting. This presentation is not sponsored or endorsed by ASCO.

<HR SIZE=1>Educational Objectives

At the conclusion of this meeting, you should be able to:
  • <LI class=body1>Review results from adjuvant trials targeting HER2<SUP>+</SUP> breast cancer and the potential for individualizing therapy based on genomics or other risk factors <LI class=body1>Summarize novel therapeutic approaches to targeting HER2 in breast cancer, including small-molecule tyrosine kinase inhibitors, dimerization inhibitors, antibody-toxin conjugates, and HSP90 inhibitors <LI class=body1>Assess the utility of angiogenesis inhibition in the treatment of metastatic breast cancer, and list agents undergoing clinical investigation <LI class=body1>Explain the rationale underlying combinations of novel targeted agents, including combinations of HER2-targeted agents with angiogenesis inhibitors, endocrine therapy, and mTOR inhibitors
  • Describe other signaling pathways that might interact with HER2 receptor signaling and the ways that mutations in these pathways might cooperate in the process of oncogenic transformation
<HR SIZE=1>CME Accreditation

Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

<HR SIZE=1>Venue

Sheraton Chicago Hotel & Towers
Sheraton Ballroom 4-5
301 E. North Water St.
Chicago, IL 60611
Phone: (312) 464-1000

<HR SIZE=1>Registration

To view registration information please Click Here

If you are unable to access the above link, copy and paste the following link into the address bar of your broswer: http://paradigmsbc.cancerconferences.com/registration.php

<HR SIZE=1>View More

For more information regarding this free CME meeting please Click Here

</TD></TR></TBODY></TABLE></TD></TR><TR><TD><TABLE cellSpacing=0 cellPadding=0 width=537 align=center border=0><TBODY><TR><TD>This activity is supported by an educational grant from Genentech BioOncology.



Physicians' Education Resource | 3500 Maple Ave., Suite 700 | Dallas, TX 75219


</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE>
Vicki is offline   Reply With Quote
Old 05-07-2007, 10:37 AM   #2
Becky
Senior Member
 
Becky's Avatar
 
Join Date: Sep 2005
Location: Stockton, NJ
Posts: 4,179
Another given during the ASCO Conference
__________________
Kind regards

Becky

Found lump via BSE
Diagnosed 8/04 at age 45
1.9cm tumor, ER+PR-, Her2 3+(rt side)
2 micromets to sentinel node
Stage 2A
left 3mm DCIS - low grade ER+PR+Her2 neg
lumpectomies 9/7/04
4DD AC followed by 4 DD taxol
Used Leukine instead of Neulasta
35 rads on right side only
4/05 started Tamoxifen
Started Herceptin 4 months after last Taxol due to
trial results and 2005 ASCO meeting & recommendations
Oophorectomy 8/05
Started Arimidex 9/05
Finished Herceptin (16 months) 9/06
Arimidex Only
Prolia every 6 months for osteopenia

NED 18 years!

Said Christopher Robin to Pooh: "You must remember this: You're braver than you believe and stronger than you seem and smarter than you think"
Becky is offline   Reply With Quote
Old 05-07-2007, 11:44 AM   #3
hutchibk
Senior Member
 
hutchibk's Avatar
 
Join Date: Oct 2005
Posts: 3,519
I forwarded this on to my onc... I know he can't go since he and wife are expecting at that time, and I bet he already knows about the conf, but I just want him to know I am on top of it too, thanks to the ladies here at Her2Support!
__________________
Brenda

 NOV 2012 - 9 yr anniversary
JULY 2012 - 7 yr anniversary stage IV (of 50...)
Nov'03~ dX stage 2B
Dec'03~ Rt side mastectomy, Her2+, ER/PR+, 10 nodes out, one node positive
Jan'04~ Taxotere/Adria/Cytoxan x 6, NED, no Rads, Tamox. 1 year, Arimadex 3 mo., NED 14 mo.
Sept'05~ micro mets lungs/chest nodes/underarm node, Switched to Aromasin, T/C/H x 7, NED 6 months - Herceptin only
Aug'06~ micro mets chest nodes, & bone spot @ C3 neck, Added Taxol to Herceptin
Feb'07~ Genetic testing, BRCA 1&2 neg
Apr'07~ MRI - two 9mm brain mets & 5 punctates, new left chest met, & small increase of bone spot C3 neck, Stopped Aromasin
May'07~ Started Tykerb/Xeloda, no WBR for now
June'07~ MRI - stable brain mets, no new mets, 9mm spots less enhanced, CA15.3 down 45.5 to 9.3 in 10 wks, Ty/Xel working magic!
Aug'07~ MRI - brain mets shrunk half, NO NEW BRAIN METS!!, TMs stable @ 9.2
Oct'07~ PET/CT & MRI show NED
Apr'08~ scans still show NED in the head, small bone spot on right iliac crest (rear pelvic bone)
Sept'08~ MRI shows activity in brain mets, completed 5 fractions/5 consecutive days of IMRT to zap the pesky buggers
Oct'08~ dropped Xeloda, switched to tri-weekly Herceptin in combo with Tykerb, extend to tri-monthly Zometa infusion
Dec'08~ Brain MRI- 4 spots reduced to punctate size, large spot shrunk by 3mm, CT of torso clear/pelvis spot stable
June'09~ new 3-4mm left cerrebellar spot zapped with IMRT targeted rads
Sept'09~ new 6mm & 1 cm spots in pituitary/optic chiasm area. Rx= 25 days of 3D conformal fractionated targeted IMRT to the tumors.
Oct'09~ 25 days of low dose 3D conformal fractionated targeted IMRT to the bone mets spot on rt. iliac crest that have been watching for 2 years. Added daily Aromasin back into treatment regimen.
Apr'10~ Brain MRI clear! But, see new small spot on adrenal gland. Change from Aromasin back to Tamoxifen.
June'10~ Tumor markers (CA15.3) dropped from 37 to 23 after one month on Tamoxifen. Continue to monitor adrenal gland spot. Remain on Tykerb/Herceptin/Tamoxifen.
Nov'10~ Radiate positive mediastinal node that was pressing on recurrent laryngeal nerve, causing paralyzed larynx and a funny voice.
Jan'11~ MRI shows possible activity or perhaps just scar tissue/necrotic increase on 3 previously treated brain spots and a pituitary spot. 5 days of IMRT on 4 spots.
Feb'11~ Enrolled in T-DM1 EAP in Denver, first treatment March 25, 2011.
Mar'11~ Finally started T-DM1 EAP in Denver at Rocky Mountain Cancer Center/Rose on Mar. 25... hallelujah.

 "I would rather be anecdotally alive than statistically dead."
hutchibk is offline   Reply With Quote
Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts
BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -7. The time now is 04:13 PM.
Contact Us - HER2 Support Group - Archive - Privacy Statement - Top

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter